vs
Esperion Therapeutics, Inc.（ESPR）与QUALYS, INC.（QLYS）财务数据对比。点击上方公司名可切换其他公司
QUALYS, INC.的季度营收约是Esperion Therapeutics, Inc.的1.0倍（$175.3M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 10.1%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 9.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
Qualys是总部位于美国加利福尼亚州福斯特城的科技企业，专注于云安全、合规管理及相关服务，为客户提供覆盖云环境的安全防护与合规解决方案，助力企业应对各类网络安全风险，满足不同行业的合规运营需求。
ESPR vs QLYS — 直观对比
营收规模更大
QLYS
是对方的1.0倍
$168.4M
营收增速更快
ESPR
高出133.6%
10.1%
两年增速更快
ESPR
近两年复合增速
9.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $175.3M |
| 净利润 | — | $53.1M |
| 毛利率 | — | 83.4% |
| 营业利润率 | 50.6% | 33.6% |
| 净利率 | — | 30.3% |
| 营收同比 | 143.7% | 10.1% |
| 净利润同比 | — | 20.9% |
| 每股收益（稀释后） | $0.32 | $1.47 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRQLYS
| Q4 25 | $168.4M | $175.3M | ||
| Q3 25 | $87.3M | $169.9M | ||
| Q2 25 | $82.4M | $164.1M | ||
| Q1 25 | $65.0M | $159.9M | ||
| Q4 24 | $69.1M | $159.2M | ||
| Q3 24 | $51.6M | $153.9M | ||
| Q2 24 | $73.8M | $148.7M | ||
| Q1 24 | $137.7M | $145.8M |
净利润ESPRQLYS
| Q4 25 | — | $53.1M | ||
| Q3 25 | $-31.3M | $50.3M | ||
| Q2 25 | $-12.7M | $47.3M | ||
| Q1 25 | $-40.5M | $47.5M | ||
| Q4 24 | — | $44.0M | ||
| Q3 24 | $-29.5M | $46.2M | ||
| Q2 24 | $-61.9M | $43.8M | ||
| Q1 24 | $61.0M | $39.7M |
毛利率ESPRQLYS
| Q4 25 | — | 83.4% | ||
| Q3 25 | — | 83.6% | ||
| Q2 25 | — | 82.4% | ||
| Q1 25 | — | 81.9% | ||
| Q4 24 | — | 81.8% | ||
| Q3 24 | — | 81.3% | ||
| Q2 24 | — | 82.2% | ||
| Q1 24 | — | 81.3% |
营业利润率ESPRQLYS
| Q4 25 | 50.6% | 33.6% | ||
| Q3 25 | -11.4% | 35.3% | ||
| Q2 25 | 8.6% | 31.3% | ||
| Q1 25 | -34.0% | 32.4% | ||
| Q4 24 | -6.4% | 31.0% | ||
| Q3 24 | -31.0% | 29.2% | ||
| Q2 24 | 3.5% | 32.3% | ||
| Q1 24 | 52.5% | 30.7% |
净利率ESPRQLYS
| Q4 25 | — | 30.3% | ||
| Q3 25 | -35.9% | 29.6% | ||
| Q2 25 | -15.4% | 28.8% | ||
| Q1 25 | -62.2% | 29.7% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | -57.2% | 30.0% | ||
| Q2 24 | -83.9% | 29.4% | ||
| Q1 24 | 44.3% | 27.2% |
每股收益（稀释后）ESPRQLYS
| Q4 25 | $0.32 | $1.47 | ||
| Q3 25 | $-0.16 | $1.39 | ||
| Q2 25 | $-0.06 | $1.29 | ||
| Q1 25 | $-0.21 | $1.29 | ||
| Q4 24 | $-0.14 | $1.19 | ||
| Q3 24 | $-0.15 | $1.24 | ||
| Q2 24 | $-0.33 | $1.17 | ||
| Q1 24 | $0.34 | $1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $250.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $561.2M |
| 总资产 | $465.9M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRQLYS
| Q4 25 | $167.9M | $250.3M | ||
| Q3 25 | $92.4M | $225.3M | ||
| Q2 25 | $86.1M | $194.0M | ||
| Q1 25 | $114.6M | $290.7M | ||
| Q4 24 | $144.8M | $232.2M | ||
| Q3 24 | $144.7M | $235.4M | ||
| Q2 24 | $189.3M | $281.2M | ||
| Q1 24 | $226.6M | $273.8M |
股东权益ESPRQLYS
| Q4 25 | $-302.0M | $561.2M | ||
| Q3 25 | $-451.4M | $529.4M | ||
| Q2 25 | $-433.5M | $508.2M | ||
| Q1 25 | $-426.2M | $498.0M | ||
| Q4 24 | $-388.7M | $477.1M | ||
| Q3 24 | $-370.2M | $449.6M | ||
| Q2 24 | $-344.2M | $427.8M | ||
| Q1 24 | $-294.3M | $404.2M |
总资产ESPRQLYS
| Q4 25 | $465.9M | $1.1B | ||
| Q3 25 | $364.0M | $1.0B | ||
| Q2 25 | $347.1M | $999.5M | ||
| Q1 25 | $324.0M | $996.5M | ||
| Q4 24 | $343.8M | $973.5M | ||
| Q3 24 | $314.1M | $908.3M | ||
| Q2 24 | $352.3M | $876.6M | ||
| Q1 24 | $373.1M | $861.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $75.7M |
| 自由现金流经营现金流 - 资本支出 | — | $74.9M |
| 自由现金流率自由现金流/营收 | — | 42.8% |
| 资本支出强度资本支出/营收 | 0.0% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 1.42× |
| 过去12个月自由现金流最近4个季度 | — | $304.4M |
8季度趋势，按日历期对齐
经营现金流ESPRQLYS
| Q4 25 | $45.2M | $75.7M | ||
| Q3 25 | $-4.3M | $90.4M | ||
| Q2 25 | $-31.4M | $33.8M | ||
| Q1 25 | $-22.6M | $109.6M | ||
| Q4 24 | $-35.0M | $47.7M | ||
| Q3 24 | $-35.3M | $61.0M | ||
| Q2 24 | $-7.2M | $49.8M | ||
| Q1 24 | $53.8M | $85.5M |
自由现金流ESPRQLYS
| Q4 25 | — | $74.9M | ||
| Q3 25 | — | $89.5M | ||
| Q2 25 | — | $32.4M | ||
| Q1 25 | — | $107.5M | ||
| Q4 24 | — | $41.9M | ||
| Q3 24 | $-35.5M | $57.6M | ||
| Q2 24 | $-7.3M | $48.8M | ||
| Q1 24 | $53.8M | $83.5M |
自由现金流率ESPRQLYS
| Q4 25 | — | 42.8% | ||
| Q3 25 | — | 52.7% | ||
| Q2 25 | — | 19.8% | ||
| Q1 25 | — | 67.3% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | -68.7% | 37.4% | ||
| Q2 24 | -9.9% | 32.8% | ||
| Q1 24 | 39.0% | 57.2% |
资本支出强度ESPRQLYS
| Q4 25 | 0.0% | 0.4% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.0% | 1.3% | ||
| Q4 24 | 0.0% | 3.7% | ||
| Q3 24 | 0.3% | 2.2% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.1% | 1.4% |
现金转化率ESPRQLYS
| Q4 25 | — | 1.42× | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | 0.71× | ||
| Q1 25 | — | 2.31× | ||
| Q4 24 | — | 1.09× | ||
| Q3 24 | — | 1.32× | ||
| Q2 24 | — | 1.14× | ||
| Q1 24 | 0.88× | 2.15× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
QLYS
| Sales Channel Through Intermediary | $88.6M | 51% |
| Sales Channel Directly To Consumer | $86.7M | 49% |
